Research Summary

I am a physician-scientist focused on developing novel immunotherapies with enhanced activity and reduced toxicity, for patients with solid cancers.

Clinically, I see patients in the Cancer Immunotherapy Program where I lead numerous early phase trials, with a particular focus on adoptive cell therapies for solid tumors (CAR-T and TCR). I have also led trials of intratumoral immunotherapy and next-generation cytokine therapy.

In the laboratory, I run an extramurally funded translational program focused on the role of cytotoxic immune effectors in anti-tumor responses as well as immune-related adverse events (IRAEs) after immunotherapy. This work spans high-resolution multiomic interrogation and functional validation using patient samples, as well as murine model systems.

Research Funding

  • March 1, 2019 - February 29, 2024 - Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K08AI139375

Education

Harvard College, Cambridge, MA, AB, 06/2000, Biochemical Sciences
Stanford University School of Medicine, Stanford, CA, MD, 06/2011, Medicine
Stanford University School of Medicine, Stanford, CA, PhD, 06/2011, Molecular and Cellular Physiology
University of California, San Francisco, CA, Residency, 06/2014, Internal Medicine
University of California, San Francisco, CA, Fellowship, 06/2017, Hematology/Oncology

Honors & Awards

  • 9/2001-6/2011
    Medical Scientist Training Program awardee
  • 3/2010
    Keystone Symposia Travel Scholarship
  • 6/2015
    UCSF Hematology/Oncology Clinical Fellow Award (selected by Medicine housestaff for patient care, teaching, professionalism)
  • 1/2016
    UCSF Hematology/Oncology 2016 Award for Excellence in Fellowship Research
  • 4/2016
    Merit Award, Conquer Cancer Foundation of American Society of Clinical Oncology
  • 6/2017
    Young Investigator Award, Conquer Cancer Foundation of American Society of Clinical Oncology
  • 5/2018
    Young Investigator Award, Bladder Cancer Advocacy Network
  • 7/2018
    Young Investigator Award, Prostate Cancer Foundation

Selected Publications

  1. Mennillo E, Kim YJ, Rusu I, Lee G, Dorman LC, Bernard-Vazquez F, Bain JL, Patel R, Andersen C, Rao A, Tamaki S, Tsui J, Shen A, Naser M, Eckalbar W, Cho SJ, Beck K, El-Nachef N, Lewin S, Selvig DR, Terdiman JP, Mahadevan U, Oh DY, Fragiadakis GK, Pisco A, Combes AJ, Kattah MG. Single-cell and spatial multi-omics identify innate and stromal modules targeted by anti-integrin therapy in ulcerative colitis. bioRxiv. 2023 Jan 22.  View on PubMed
  2. Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, Yuen B, Dalmas O, Heeringa K, Sennino B, Conroy A, Bethune MT, Mende I, White W, Kukreja M, Gunturu S, Humphrey E, Hussaini A, An D, Litterman AJ, Quach BB, Ng AHC, Lu Y, Smith C, Campbell KM, Anaya D, Skrdlant L, Huang EY, Mendoza V, Mathur J, Dengler L, Purandare B, Moot R, Yi MC, Funke R, Sibley A, Stallings-Schmitt T, Oh DY, Chmielowski B, Abedi M, Yuan Y, Sosman JA, Lee SM, Schoenfeld AJ, Baltimore D, Heath JR, Franzusoff A, Ribas A, Rao AV, Mandl SJ. Non-viral precision T?cell receptor replacement for personalized cell therapy. Nature. 2022 Nov 10.  View on PubMed
  3. Kwon H, Schafer JM, Song NJ, Kaneko S, Li A, Xiao T, Ma A, Allen C, Das K, Zhou L, Riesenberg B, Chang Y, Weltge P, Velegraki M, Oh DY, Fong L, Ma Q, Sundi D, Chung D, Li X, Li Z. Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer. Sci Immunol. 2022 07; 7(73):eabq2630.  View on PubMed
  4. Susan F. Slovin, Tanya B. Dorff, Gerald Steven Falchook, Xiao X. Wei, Xin Gao, Rana R. McKay, David Yoonsuk Oh, Andreas Georg Wibmer, Matthew A. Spear, Joanne McCaigue, Devon J. Shedlock, Manjima Dhar, Julia Coronella, Christopher E. Martin, Majid Ghodussi, Ann Murphy, Eric M. Ostertag. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2022 Feb 20; 40(6_suppl):98-98.  View on PubMed
  5. Wei J, Oh DY, Evans MJ. Preparation of Radiolabeled Antibodies for Nuclear Medicine Applications in Immuno-Oncology. Methods Mol Biol. 2022; 2393:829-839.  View on PubMed
  6. Oh DY, Fong L. Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox. Immunity. 2021 12 14; 54(12):2701-2711.  View on PubMed
  7. Oh DY, Fong L, Newell EW, Turk MJ, Chi H, Chang HY, Satpathy AT, Fairfax B, Silva-Santos B, Lantz O. Toward a better understanding of T cells in cancer. Cancer Cell. 2021 12 13; 39(12):1549-1552.  View on PubMed
  8. Zhao N, Bardine C, Louren?o AL, Wang YH, Huang Y, Cleary SJ, Wilson DM, Oh DY, Fong L, Looney MR, Evans MJ, Craik CS. In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. ACS Cent Sci. 2021 Oct 27; 7(10):1638-1649.  View on PubMed
  9. Keenan BP, VAN Loon K, Khilnani AD, Fidelman N, Behr SC, Atreya CE, Oh DY. Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy. Anticancer Res. 2021 Jun; 41(6):2985-2992.  View on PubMed
  10. Apostolia Maria Tsimberidou, Alexandra Drakaki, Danny Khalil, Shivaani Kummar, F. Stephen Hodi, David Yoonsuk Oh, Christopher R. Cabanski, Michael Tezlaff, Theresa LaVallee, Marko Spasic, Leo Nissola, Lacey J. Kitch, Nicholas L. Bayless, Cheryl Selinsky, Jennifer C Ayran, Jill O'Donnell-Tormey, Vanessa M. Hubbard-Lucey, Ute Dugan, James Patrick Allison, Padmanee Sharma. An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):2573-2573.  View on PubMed
  11. Divya V Natesan, Li Zhang, David Yoonsuk Oh, Sima P. Porten, Maxwell Meng, Raj Pruthi, Matthew R. Cooperberg, Peter Carroll, Jonathan Chou, Hala Borno, Rohit Bose, Arpita Desai, Daniel H Kwon, Anthony C. Wong, Felix Y Feng, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin. Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423). Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):e16510-e16510.  View on PubMed
  12. de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. J Immunother Cancer. 2021 05; 9(5).  View on PubMed
  13. Baik AH, Tsai KK, Oh DY, Aras MA. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clin Sci (Lond). 2021 03 12; 135(5):703-724.  View on PubMed
  14. Oh DY. CD38 as a Novel Immunosuppressive Target in Prostate Cancer. Eur Urol. 2021 06; 79(6):747-749.  View on PubMed
  15. Vadim S Koshkin, Divya Natesan, Li Zhang, David Yoonsuk Oh, Sima P. Porten, Maxwell Meng, Raj Pruthi, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander. Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):442-442.  View on PubMed
  16. Ivan de Kouchkovsky, Li Zhang, Errol Philip, Francis Wright, Daniel Myung Kim, Divya Natesan, Daniel Kwon, Hansen Ho, Son Ho, Emily Chan, Sima P. Porten, Arpita Desai, Franklin W. Huang, Jonathan Chou, David Yoonsuk Oh, Raj Pruthi, Lawrence Fong, Eric Jay Small, Terence W. Friedlander, Vadim S Koshkin. TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):476-476.  View on PubMed
  17. Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L. Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients. Cancer Immunol Immunother. 2021 Jul; 70(7):2095-2102.  View on PubMed
  18. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sj?str?m M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 12 01; 26(23):6204-6214.  View on PubMed
  19. Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L. Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T. Cancer Immunol Res. 2020 12; 8(12):1496-1507.  View on PubMed
  20. Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Mol Imaging Biol. 2020 12; 22(6):1553-1561.  View on PubMed

Go to UCSF Profiles, powered by CTSI